A bruised Circassia offloads debt by returning COPD drugs to AstraZeneca

It had a glittering £200 million mega-IPO on the London Stock Exchange in 2014, but failure after trial failure blighted its prospects. A battered Circassia Pharmaceuticals, by 2017 reliant on its asthma management device Niox for revenue, turned to fellow UK drugmaker AstraZeneca to infuse some oxygen into its starved pipeline.